Excalibur Management Corp Lowers Stake in Stryker Corporation $SYK

by · The Cerbat Gem

Excalibur Management Corp lessened its stake in Stryker Corporation (NYSE:SYK – Free Report) by 5.8% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 3,092 shares of the medical technology company’s stock after selling 190 shares during the quarter. Excalibur Management Corp’s holdings in Stryker were worth $1,223,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in SYK. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Stryker in the second quarter valued at approximately $26,000. Sachetta LLC raised its position in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares in the last quarter. Ridgewood Investments LLC lifted its holdings in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares during the period. Ransom Advisory Ltd bought a new position in shares of Stryker during the 1st quarter worth $37,000. Finally, Solstein Capital LLC purchased a new position in shares of Stryker during the second quarter valued at $43,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Evercore ISI lowered their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. BTIG Research increased their price objective on shares of Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Truist Financial restated a “hold” rating and set a $392.00 target price (down previously from $407.00) on shares of Stryker in a report on Monday. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a report on Monday. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $433.37.

View Our Latest Stock Report on Stryker

Stryker Price Performance

Shares of SYK opened at $353.42 on Friday. The company has a 50 day moving average of $375.35 and a two-hundred day moving average of $380.88. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a market cap of $135.16 billion, a price-to-earnings ratio of 46.81, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

See Also

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).